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Type 2 diabetes mellitus (T2DM) is a serious health problem, and the number of affected persons is increasing
annually worldwide. Obesity is the main cause of diabetes. As an individual gain weight, adipocytes are observed to
become bigger. Hypotrophic adipocytes shows decreased adiponectin secretion and increased free fatty acids and
inflammatory adipokines, which leads to lowered insulin sensitivity and metabolic activity. In contrast, having smaller
and fewer adipocytes lead to increases in insulin sensitivity and adiponectin secretion and decreases in the release of
inflammatory cytokines. Therefore, increasing the number of smaller adipocytes has been suggested as an effective
strategy to prevent and treatment of T2DM. Although thiazolidinediones, such as troglitazone and pioglitazone, which
are used currently to treat T2DM, can improve insulin sensitivity by increasing the number of small adipocytes, the
side effects of these drugs include weight gain and liver failure. As an alternative treatment for T2DM, polyphenolic
compounds, such as nobiletin and sakuranetin, reportedly induce preadipocytes to become small adipocytes. In addi-
tion, our recent study showed that the polyphenol cyanidin-3-glucoside (Cy3G), an anthocyanin, similarly induces
3T3-L1 preadipocytes to become small adipocytes, and several other researchers have obtained diverse evidence that
supports the efficacy of Cy3G in the prevention or treatment of T2DM. Here, we summarize the activities of Cy3G
that may support its use in the prevention of T2DM, focusing on the drug’s effect on adipocytes.
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Introduction
Type 2 diabetes mellitus (T2DM) is a serious health
problem, comprising 75%∼80% of all cases of dia-
betes. The prevalence of T2DM is estimated to reach
350 million cases by the year 2030, and the expen-
diture for diabetes treatment is projected to be $132
billion in the United States alone (Guilherme et al.,
2008). Obesity is the main cause of T2DM (Kopel-
man, 2000; Nawrocki and Scherer, 2005), and adi-
pocytes play an important role in maintaining lipid and
glucose homeostasis and energy balance by storing
triglycerides and releasing free fatty acids and adi-
pokines. In obese persons, adipocytes become bigger
and more numerous, accumulating triglycerides and
increasing the secretion of inflammatory adipokines,
including tumor necrosis factor (TNF-α), interleukin
(IL-6), and monocyte chemotactic protein 1 (MCP-
1). These increases lead to the development of insulin
resistance, in which cells fail to respond to otherwise
normal amounts of insulin; insulin resistance arises due
to the inhibition of insulin-stimulated tyrosine phos-
phorylation, which is triggered through the activation
of c-Jun NH2 terminal kinase (JNK) (Nawrocki and
Scherer, 2005; Zou and Shao, 2008). In addition, hy-
pertrophic adipocytes demonstrate decreased secretion
of adiponectin, a hormone that regulates energy expen-
diture, glucose homeostasis, and insulin sensitivity
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(Zou and Shao, 2008). As a countermeasure, increas-
ing the number of small adipocytes has been suggested
as a strategy to decrease insulin resistance, given that
smaller adipocytes secrete more adiponectin and less
inflammatory cytokines than do larger ones (Smith,
2003).
Thiazolidinediones (TZDs) such as troglitazone and
pioglitazone, a class of drugs currently used in the
treatment of T2DM, ameliorate insulin resistance by
increasing the number of small adipocytes (Saltiel and
Olefsky, 1996). However, because the adverse effects
of TZDs include weight gain and edema, alternative
methods for inducing the differentiation of preadi-
pocytes into small adipocytes are desired. In this con-
text, polyphenolic compounds have gained attention
recently (Leiherer et al., 2013). Like TZDs, the poly-
phenols nobiletin (Saito et al., 2007) and sakuranetin
(Saito et al., 2008) induce preadipocytes to become
small adipocytes.
Anthocyanins, one group of polyphenolic compounds,
are present as the water-soluble pigments in numerous
colorful fruits and vegetables, including black soy-
beans, blueberries, and grapes. For the US population,
the estimated daily intake of anthocyanins is 180-215
mg (Kühnau, 1976). Cyanidin is the most widespread
anthocyanin in nature (Parkinson and Brown, 1981)
and exists in plants in its glycated form, cyanidin-3-
glucoside (Cy3G) (Fig. 1). Several studies have dis-
closed the numerous health benefits of Cy3G, includ-
ing anti-oxidative (Tsuda et al., 1998; Slavin et al.,
2013) and anti-inflammatory (Kim et al., 2008) ef-
fects. Pharmacokinetic studies in rats and humans
(Miyazawa et al., 1999; Cao et al., 2001) have re-
vealed that absorbed Cy3G is present in its unchanged,
glycated form in plasma and urine. In addition, an
investigation into the distribution of anthocyanins in
various organs indicated that Cy3G is present in
adipose tissue (Felgines et al., 2009). Together these
studies clearly demonstrate that Cy3G can̶and does
̶reach adipocytes through the blood serum.
In our own recent study, we found that Cy3G can
ameliorate T2DM by inducing 3T3-L1 preadipocytes
to differentiate into small (rather than large) adipo-
cytes, thereby increasing the secretion of adiponectin
and decreasing the release of TNF-α (Matsukawa et
al., 2015). Many other researchers similarly assert
that Cy3G is likely to be effective in the treatment and
prevention of T2DM (Sasaki et al., 2007; Guo et al.,
2008; Wei et al., 2010; Guo et al., 2012; Matsukawa et
al., 2015). In this review, we summarize the T2DM-
preventive activities of Cy3G, focusing on its effects
on adipocytes.
1. The effect of cyanidin-3-glucoside
on the secretion of adipokines
Adipocytes function as an endocrine organ, and adi-
pokines, the cytokines derived from adipocytes, regu-
late energy balance, insulin sensitivity, lipid metabo-
lism, and inflammation (Zou and Shao, 2008). In-
flammatory adipokines, such as TNF-α, IL-6, and MCP-
1, decrease insulin sensitivity by inhibiting insulin-
stimulated insulin receptor (IR) phosphorylation through
the JNK pathway. In contrast, adiponectin, another
adipokine, activates energy expenditure and promotes
insulin sensitivity (Nawrocki and Scherer, 2005; Zou
and Shao, 2008). Small adipocytes secrete more adi-
ponectin and less inflammatory adipokines than do
their larger counterparts (Smith, 2003). In fact, TZDs,
a class of current therapeutic drugs for T2DM, increase
adiponectin levels and decrease those of inflammatory
cytokines by promoting the differentiation into small
adipocytes (Saltiel and Olefsky, 1996).
Like TZDs, Cy3G increases the secretion of adi-
ponectin in vivo (Guo et al., 2012) and in vitro (Matsu-
kawa et al., 2015). Adiponectin activates mitochon-
drial biogenesis and oxidative capacity in skeletal mus-
cle by increasing the protein and mRNA expression of
peroxisome proliferator-activated receptor γ coacti-
vator α (PGC-1α) (Iwabu et al., 2010). Consistent
with these results, the addition of culture medium from
Cy3G-treated adipocytes increased the expression of
PGC-1α in C2C12 myotubes, a cellular model of
skeletal muscle (Matsukawa et al., 2015). In addition
to its effects on adiponectin, Cy3G modulates the se-
cretion of inflammatory adipokines. In both in vivo
J. Dev. Sus. Agr. 11 (1)32
Fig. 1. Chemical structure of cyanidin-3-glucoside
(Cy3G).
and in vitro systems, Cy3G treatment reduces the se-
cretion of TNF-α (Guo et al., 2012; Matsukawa et al.,
2015) as well as of MCP-1, which leads to inflam-
mation through the infiltration of macrophages into
adipose tissue (Guo et al., 2012). These combined
results imply that Cy3G activates metabolic activity
and alleviates insulin resistance and inflammation by
regulating the secretion of adipokines.
2. The effect of cyanidin-3-glucoside
on glucose uptake
Glucose uptake has an important role in mainte-
nance of blood glucose levels. In general, after insulin
is secreted from the β cells of the pancreas, it binds to
IR and thus activates the phosphorylation of the insulin
signaling cascade, which includes IR, insulin receptor
substrate 1 (IRS-1), and Akt (Huang and Czech, 2007).
The activation of insulin signaling promotes the trans-
location of glucose transporter 4 (GLUT4) into cell
membranes. During insulin resistance, a hallmark of
T2DM, cells fail to respond to the otherwise normal
actions of insulin, leading to the inhibition of GLUT4
translocation and therefore decreased glucose uptake in
adipocytes and myocytes (Huang and Czech, 2007).
As evidence of its potential use in treating T2DM,
feeding Cy3G to db/db mice, an animal model of
diabetes, lowered their fasting glucose levels (Guo et
al., 2012). In addition, glucose and insulin tolerance
tests revealed that Cy3G improved the insulin sensi-
tivity and glucose clearance of db/db mice (Guo et al.
2012).
Like the db/db mouse experiments, our previous
study (Matsukawa et al., 2015) supports the claim that
Cy3G decreases the serum glucose level during
T2DM. Using 3T3-L1 cells, an in vitro model of adi-
pocytes differentiation, we found that Cy3G increases
their insulin sensitivity and glucose uptake. In addi-
tion, we revealed that the expression of GLUT4 in 3T3-
L1 adipocytes were up-regulated by Cy3G treatment
during adipocytes differentiation; GLUT4 expression
is downregulated in the adipose tissue of patients with
T2DM (Yang et al., 2005). Furthermore we found
that Cy3G increases the gene expression of CCAAT/
enhancer binding protein α (C/EBPα) (Matsukawa et
al., 2015). C/EBPα influences not only adipocyte dif-
ferentiation but also insulin sensitivity: C/EBPα binds
to the promotors of the insulin receptor and GLUT4
genes and thus upregulates their expression (Wu et al.,
1999; Karnieli and Armoni, 2008). Therefore, Cy3G
appears to promote the insulin sensitivity of adipocytes
by increasing the gene expression of C/EBPα and thus
of GLUT4.
Several adipokines, including TNF-α and retinol
binding protein 4 (RBP4), decrease the glucose uptake
ability and insulin sensitivity of adipocytes and my-
ocytes (Zou and Shao, 2008). In particular, TNF-α
suppresses the expression of many proteins associated
with glucose uptake, including IR, IRS-1, and GLUT4,
by activating JNK and thus suppressing peroxisome
proliferator-activated receptor γ (PPARγ) and C/EBPα,
which are transcriptional factor for regulating the gene
expression of associated with various adipocyte func-
tion, including GLUT4 and adiponectin (Cawthorn and
Sethi, 2008; Cristancho and Lazar, 2011). In addition,
TNF-α promotes the generation of reactive oxygen
species, which are involved in JNK activation and thus
play an important role in the progression of insulin
resistance (Houstis et al., 2006). However, because
Cy3G has anti-oxidant activity (Tsuda et al., 1998;
Slavin et al., 2013), it protects against a TNF-α-in-
duced decrease in insulin sensitivity by inhibiting the
activation of JNK (Guo et al., 2008). Furthermore,
although the adipokine RBP4 decreases insulin sensi-
tivity and glucose uptake by inhibiting GLUT4 expres-
sion (Yang et al., 2005), Cy3G curtails the secretion of
RBP4 (Sasaki et al., 2007). Overall, these results in-
dicate that Cy3G promotes glucose uptake and insulin
sensitivity by increasing GLUT4 expression and in-
hibiting the activation of the inflammatory reaction.
3. The effect of cyanidin-3-glucoside
on adipocyte differentiation
Adipocyte differentiation plays an important role in
the regulation of adipokine secretion and in the insulin
sensitivity of adipocytes (Farmer, 2006; Siersbaek et
al., 2012). In turn, adipokine secretion is regulated by
PPARγ and C/EBPα, which also modulate adipocyte
differentiation (Wu et al., 1999; Farmer, 2006). Dur-
ing terminal adipocyte differentiation, PPARγ and
C/EBPα regulate the gene expression of various meta-
bolic proteins and adipokines associated with adipo-
cyte function, including GLUT4, fatty acid-binding
protein 4, and adiponectin (Cristancho and Lazar,
2011). In particular, a complex comprising PPARγ,
PPARγ ligand, and retinoic acid receptor binds to
peroxisome proliferator response elements (PPRE) and
leads to their transcription (Houseknecht et al., 2002).
TZDs act as PPARγ agonists by activating the tran-
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scriptional activity of PPARγ and thus increasing in-
sulin sensitivity and promoting adipocyte differen-
tiation (Saltiel and Olefsky, 1996). Similar to TZDs,
polyphenols such as phloretin (Hassan et al., 2008)
and flavanone (Saito et al., 2009) exhibit PPARγ
agonist activity, induce PPARγ transcriptional activity,
and promote adipocyte differentiation.
In our previous study (Matsukawa et al., 2015),
Cy3G induced the differentiation of preadipocytes to
small adipocytes by increasing the expression of
PPARγ and C/EBPα. Cy3G, however, does not act as
a PPARγ agonist. Instead, Cy3G increases the expres-
sion of C/EBPβ (unpublished data); C/EBPβ is im-
portant for early-phase adipocyte differentiation and
regulates PPARγ and C/EBPα (Siersbaek et al., 2012).
Like Cy3G, the polyphenol nobiletin does not act as a
PPARγ agonist but instead promotes adipocyte differ-
entiation by increasing C/EBPβ expression through the
activation of cAMP-responsive element binding pro-
tein (Saito et al. 2007). Cy3G may likewise influence
the early phase of adipocyte differentiation, but addi-
tional research is needed to reveal the underlying
mechanism.
Conclusion
Cy3G is an anthocyanin that might be effective for
preventing or ameliorating T2DM owing to its abilities
to activate insulin sensitivity, glucose uptake, and adi-
ponectin secretion and to decrease the secretion of
RBP4 and inflammatory cytokines, such as TNF-α and
MCP-1. These effects of Cy3G are achieved through
the promotion of adipocytes differentiation, given that
Cy3G upregulates the expression of PPARγ and
C/EBPα, which are key modulators of adipocyte dif-
ferentiation (Fig. 2). However, Cy3G does not func-
tion as a PPARγ agonist, as do TZDs. Additional re-
search is needed to clearly define the the mechanism
underlying the function of Cy3G and how this com-
pound can be used effectively in the treatment of
T2DM. The use of vegetables and fruits, such as black
soybeans, blueberries, and grapes, as sources of Cy3G
contributes to the development of agriculture.
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